insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy.

1/5 보강
Brachytherapy 📖 저널 OA 11.4% 2022: 0/1 OA 2025: 0/6 OA 2026: 4/26 OA 2022~2026 2026 Vol.25(1) p. 15-23
Retraction 확인
출처
PubMed DOI

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
49 patients had favorable and 66 had unfavorable intermediate-risk disease.
I · Intervention 중재 / 시술
definitive HDR brachytherapy as monotherapy and had pretreatment MRI within 6 months
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The addition of ADT significantly decreased the odds of treatment failure in these patients. These findings highlight the value of MRI-based risk stratification and suggest that treatment intensification options such as ADT could be considered to optimize treatment outcomes.

Oyeniyi JF, Lee JS, Shen C, Loving BA, Nandalur SR, Thompson AB

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

[OBJECTIVE] To identify MRI features associated with treatment failure in intermediate-risk prostate cancer patients treated with HDR brachytherapy monotherapy.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 39
  • p-value p < 0.001
  • p-value p = 0.043
  • OR 3.9

이 논문을 인용하기

↓ .bib ↓ .ris
APA Oyeniyi JF, Lee JS, et al. (2026). MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy.. Brachytherapy, 25(1), 15-23. https://doi.org/10.1016/j.brachy.2025.10.012
MLA Oyeniyi JF, et al.. "MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy.." Brachytherapy, vol. 25, no. 1, 2026, pp. 15-23.
PMID 41266232 ↗
DOI 10.1016/j.brachy.2025.10.012

Abstract

[OBJECTIVE] To identify MRI features associated with treatment failure in intermediate-risk prostate cancer patients treated with HDR brachytherapy monotherapy.

[METHODS] We analyzed 115 men with intermediate-risk prostate cancer who underwent definitive HDR brachytherapy as monotherapy and had pretreatment MRI within 6 months. MRI features assessed included lesion size, focality, location, capsular contact (yes vs. no, with no gross extracapsular extension), length of capsular contact, and PIRADS score. Univariable and multivariate logistic regression analyses were performed to identify MRI features associated with treatment failure, defined as biochemical recurrence and/or local recurrence.

[RESULTS] The median age was 64 years, and median pretreatment PSA 5.95 ng/mL; 49 patients had favorable and 66 had unfavorable intermediate-risk disease. At 47 months median follow-up, 19 patients (16.5%) experienced treatment failure. MRI features associated with treatment failure on UVA included lesion size (OR: 3.9, CI: 1.8-8.8, p < 0.001), multifocality (OR: 2.9, CI: 1.0-7.9, p = 0.043), capsular contact (OR: 64.3, CI: 8.1-510.0, p < 0.001), capsular contact length ≥1 cm (OR: 5.0, CI: 1.6-15.7, p = 0.006), and PIRADS 5 (OR: 16.7, CI: 2.7-324.8, p = 0.011). On MVA, only capsular contact remained significant (OR: 57.2, CI: 9.5-106.2, p < 0.001). In patients with capsular contact (n = 39), ADT significantly reduced treatment failure (OR: 0.101, CI: 0.002-0.912, p = 0.023).

[CONCLUSION] Capsular contact on MRI is a strong independent predictor of treatment failure in intermediate-risk prostate cancer patients undergoing HDR brachytherapy as monotherapy. The addition of ADT significantly decreased the odds of treatment failure in these patients. These findings highlight the value of MRI-based risk stratification and suggest that treatment intensification options such as ADT could be considered to optimize treatment outcomes.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반